Rosemary Rochford, PhD, Vice President for Research
Research at Upstate
is guided by four disease- based pillars that stimulate cross-departmental collaboration and inter- disciplinary
research. Our researchers are based in departments, but their work can also be thought of in the context of the pillars or in
the basic sciences.
Office of Vice President for Research
Rosemary Rochford, PhD
766 Irving Ave.
Syracuse, NY 13210
315 464-5453
Current Appointments
- Vice President for Research of Research Administration
- Vice President for Research
Hospital Campus
- Downtown
Research Programs and Affiliations
- Biomedical Sciences Program
- Cancer Research Institute
- Microbiology and Immunology
- Research Pillars
Education & Fellowships
- PhD: University of California at Irvine, 1989
Research Interests
- Etiology of viral-associated malignancies, gammaherpesvirus pathogenesis.
HealthLinkOnAir Radio Interview
5/15/13 How will the NIH grant funding sequester affect local research?3/13/13 Challenges in Cancer Research in Africa
4/29/12 Bird flu virus controversy
Publications
Link to PubMed (Opens new window. Close the PubMed window to return to this page.)
Research Abstract
Infection with Epstein-Barr virus (EBV) is associated with a number of malignancies including endemic Burkitt’s lymphoma (eBL), the most common childhood cancer in sub-Saharan Africa. The current research in my laboratory is directed towards three main areas of investigation. First, we have established a field research project based in Kisumu, Kenya to understand the how the interaction of co-factors including holoendemic malaria in the context of early primary infection with EBV lead to the emergence of eBL. Second, we are utilizing infection of mice with the murine gammaherpesvirus-68 (MHV-68) to examine early events in gammaherpesvirus pathogenesis as well as to model virus-parasite interactions. Finally, we are developing mechanism-based therapies for the treatment of BL and other AIDS-associated non-Hodgkin’s lymphomas that address the unique needs in resource-poor settings using a preclincal model. In this preclinical model, SCID mice are engrafted with BL lines that have been in short-term culture and tagged with luciferase. We are using bioluminescent imaging to monitor tumor growth and response to treatment and to determine whether targeting of angiogenesis by adopting a metronomic schedule of therapy can induce remission and reduce toxicity.